President Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers, according to CNBC. The announcement, expected today, would extend the administration's push to link US drug prices to the cheaper rates paid in other countries.
The deals, if confirmed, would involve a group of pharmaceutical companies, though CNBC did not name them. The report did not specify which drugs would be affected or the exact pricing terms.
A push to tie US prices to foreign benchmarks
The reported deals build on the Trump administration's broader strategy of using international reference pricing to lower what Americans pay for prescription drugs. By aligning US prices with those in other nations, the administration aims to reduce costs for consumers and the federal government.
CNBC's report, published at 17:20 UTC on August 31, 2026, provides no further details on the mechanics of the deals or the timeline for implementation. It is unclear whether the announcement will include specific drug names or savings estimates.
What remains unknown
The report leaves several questions open. Which drugmakers are involved? What drugs are covered? And when will the deals take effect? CNBC's account does not address these points, and no official confirmation has been cited.
As of this writing, the White House has not publicly commented on the report. The announcement, if it occurs, could come later today or in the coming days.